"Pharmaceutical Speed Reader" people Fu PharmaceuticalSa-Ylun China was approved deqi medicine to complete the C round of financing.

July 20, 2020 / Medical Information List: ManFu Pharmaceuticals Rema Julun China was approved for listing; Qilu Pharmaceuticals "Aripitan Capsules" was approved for the first time; Ai Pharmaceuticals today announced the completion of $97 million C round financing; Anda Biotech new crown virus extraction kit was certified by the European Union... Daily fresh medicine to hear medical news, fast-reading society with you to pay attention! Part 1 Policy Briefing Beijing Central Risk Area Clearance Beijing Municipal Committee Vice Minister of Propaganda Xu Hejian introduced that Beijing has been 14 consecutive days no new local confirmed cases reported, local confirmed cases cured nearly 2/3 of the total number of confirmed cases, the middle risk area cleared zero.
(Beijing epidemic prevention and control press conference) the state sent a strong grass-roots: prohibit higher-level hospitals "siphon-type" to dig up talent recently, the Ministry of Human Resources and Social Security, the National Health and Welfare Commission issued "on doing a good job in 2020 county-level and primary health care institutions open recruitment of college graduates notice", for the recruitment of grass-roots medical institutions to prepare, subsidies and other preferential policies, and explicitly proposed to prohibit higher-level medical and health institutions from the lower-level medical and health institutions to "siphon-style" to dig talent.
(Human Resources and Social Security Department, National Health and Health Commission) Part 2 production and observation of Eddie Pharmaceuticals today the company's board listing 20, Jiangsu Eddie Pharmaceuticals officially listed in the company board listing, the number of shares issued does not exceed 90 million shares, the issue price of 13.99 yuan / share, the corresponding price-earnings ratio of 285.07 times.
(Pharmaceutical Rubik's Cube) Genting Xinyao applied for listing on the Hong Kong Stock Exchange And Submitted a listing application to the HkEx, with Goldman Sachs and Bank of America as co-sponsors.
follows the announcement on June 5th that Genting Xinyao has completed a $310 million round C financing, which will be used to advance clinical research and development of Genting's new Innovative Pharmaceutical Products Pipeline and build a strong commercial infrastructure for the next phase of growth.
(immediate medicine) national medicine consistent: to be publicly assigned to The 100% equity of The Great Square National Medicine unanimously issued a notice that the holding subsidiary State University Pharmacy intends to publicly transfer Liaoning Chengda to hold 100% of chengda square, the listing floor price of 1.86 billion yuan.
(Sina Pharmaceutical News) Deqi Pharmaceuticals announced the completion of $97 million C round financing to accelerate the development and commercialization of new drug Research and Development de qi Pharmaceuticals announced the completion of 97 million U.S. dollars of C-round financing.
the funds raised will be used to consolidate and strengthen the company's research and development pipeline, promote the continuous clinical development of blood tumors and solid tumor products, continue to enhance the ability of early drug research and development, and further enhance the company's commercial operations in the Asia-Pacific market.
(Pharmaceutical Mission Hills) Part 3 Pharmaceutical Information Hengrui Pharmaceutical Injection With Carelli Zhuzumab Drug Clinical Trial Approval Notice Hengrui Pharmaceuticals announced that the company and subsidiaries Suzhou Shengdia Biopharmaceuticals, Shanghai Hengrui Pharmaceuticals recently received the Approval Of Drug Clinical Trials issued by the State Drug Administration, agreed to carry out CarelliZhuZumabinau combined chemotherapy treatment of the new complementary treatment of early or local advanced three-negative breast cancer clinical trial.
(Sina Pharmaceutical News) Hengrui Pharmaceutical Malay-Oxine tablets received the drug supplement application approval notice Hengrui Pharmaceuticals issued a notice that the company recently received the Approval of the State Drug Administration issued the "Drug Supplement Application Approval Notice", approved the Malay acid pickle tablet revision specification of the supplementary application.
(Sina Pharmaceutical News) Tianshili: Shubili tablets through generic drug consistency evaluation Tianshili issued a notice that the company's wholly-owned subsidiary Jiangsu Tiyi recently received the State Drug Administration issued on the Shubili tablet 100mg specifications of the "drug supplement application approval notice", the drug through the generic drug consistency evaluation.
(Sina Pharmaceutical News) People's Fu Pharmaceuticals Remaajun China was approved for listing on the 20th, according to the NMPA drug approval notice, Human Fu Pharmaceuticals China's new class 1 drug - sedative / anaesthetic - injection of benzodiazepine was approved for listing, after July 2 this year, the drug was approved by the FDA to induce and maintain the medical procedures for adult patients in the medical procedure.
(immediate drug news) Qilu Pharmaceutical "Aripitan capsule" first imitation approved Qilu Pharmaceutical 4 generic drug Aripitan capsule signed by the State Drug Administration approved the listing, as passed by consistency evaluation, and for the first imitation in China.
Arepitam is a highly selective P-substance neurokinetic peptide 1 receptor antagonist that is clinically suitable for the prevention of acute and late-onset nausea and vomiting during the initial and repeated treatment of highly vomiting antitumor chemotherapy.
(Pharmaceutical Rubik's Cube) Stone Pharmaceutical Group "Mesulfoacid Imartini tablets" through the consistency evaluation of the stone drug group methalacid Imadinib tablets through consistency evaluation.
Imartinib is an oral tyrosine kinase inhibitor drug, is a first-line drug for the treatment of chronic myeloid leukemia (CML), can make CML patients 10 years survival rate of 85% to 90%, greatly extended the life cycle of patients, known as "slow-grain leukemia life-saving drugs."
(Pharma Rubik's Cube) 4 new drug listing applications to be included in the priority review from Hengrui, Junshi ... On the 20th, CDE's official website announced that four new drug applications were to be included in the priority review, namely Hutchison Whampoa's Wallitini tablets, Hengrui Pharmaceuticals' sea-cupupaepa ethanolamine tablets, Keystone Pharmaceuticals' Apothini tablets and Junshi Bio's Telepuri mono-anti-injection sinned.
(Pharma Cube) Syanda Biotech's new crown virus extraction kit has been certified by the European Union, According to the company's research and development of PHASIFY ™ VIRAL RNA extraction kit has been officially certified by the European Union.
this logo demonstrates that PHASIFY ™ Viral meets the European in vitro diagnostic equipment standards (98/79/EC) and has access to the EU market and other CE-approved regions.
( New Study: New coronavirus-specific immune T cells can also be detected in uninfected populations, the team from duke-Singapore National University School of Medicine published the latest research results in Nature, the first time revealed COVID-19 recovery phase OF SARS-CoV-2 structural and non-structural regions of The T-cell response, found the presence of CD4 and CD8T identifiable NP protein.
unexpected, the SARS-CoV-2-specific T-cell was also detected in uninfected populations, and the specific T cells in SARS rehabilitation patients had strong cross-reaction stoicism with SARS-CoV-2.
(Biodiscovery)